Table 1.
Patient characteristics and treatment specifics.
| Percent patients (n = 108) | |
|---|---|
| Age (years): median 74 (55–91) | |
| <60 | 6 |
| 60–69 | 24 |
| 70–79 | 52 |
| ≥80 | 19 |
| Race | |
| White | 47 |
| Black | 42 |
| Hispanic | 3 |
| Asian | 2 |
| Other | 6 |
| Pre-Tx prostate-specific antigen (ng/ml): median 9.1 (0.86–39.8) | |
| ≤10 | 51 |
| >10 and ≤20 | 34 |
| >20 | 15 |
| T stage | |
| T1c | 46 |
| T2a | 12 |
| T2b | 28 |
| T2c | 13 |
| T3 | 1 |
| Gleason score | |
| 6 | 9 |
| 7 | 51 |
| 8 | 25 |
| 9 | 15 |
| Charlson comorbidity index | |
| 0–1 | 75 |
| 2–3 | 23 |
| 4 | 3 |
| Risk group (D’Amico) | |
| Low | 4 |
| Intermediate | 42 |
| High | 55 |
| Hormone therapy | |
| Yes | 63 |
| No | 37 |
| Anti-coagulation/-platelet therapy | |
| Anticoagulation | 8 |
| Antiplatelet | 48 |
| Intensity-modulated radiation therapy dose | |
| 45 Gy | 78 |
| 50.4 Gy | 19 |
| Other | 3 |